We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Betulin Suppresses Osteoclast Formation via Down-Regulating NFATc1.
- Authors
Kim, Kwang-Jin; Lee, Yongjin; Hwang, Hae-Gwang; Sung, Sang Hyun; Lee, Mina; Son, Young-Jin
- Abstract
Osteoporosis is a disease characterized by osteoclast-mediated low bone mass. The modulation of osteoclasts is important for the prevention or therapeutic treatment of loss of bone mass. Osteoclasts, which are bone-resorbing multinucleated cells, are differentiated from the hematopoietic stem cell monocyte/macrophage lineage by Receptor activator of nuclear factor kappa-B ligand <monospace>(</monospace>RANKL) expressed from osteoblasts and stromal cells. RANKL signaling ultimately activates nuclear factor of activated T Cells 1 <monospace>(</monospace>NFATc1), which is a master transcription factor in osteoclastogenesis. Betulin, a lupine type pentacyclic triterpenoid, was isolated from the bark of <italic>Betula platyphylla</italic>. Betulin inhibited RANKL-mediated osteoclast differentiation by downregulating NFATc1. Betulin may serve as a useful structural scaffold in the therapeutic agent development to prevention/treatment the osteoclast-mediated bone disorder.
- Subjects
BETULIN; OSTEOPOROSIS treatment; TRANCE protein; OSTEOBLASTS; TREATMENT of bone diseases; THERAPEUTICS
- Publication
Journal of Clinical Medicine, 2018, Vol 7, Issue 6, p154
- ISSN
2077-0383
- Publication type
Article
- DOI
10.3390/jcm7060154